7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Tang L et al. | Effects of different magnitudes of mechanical strain on Osteoblasts in vitro. | 2006 | Biochem. Biophys. Res. Commun. | pmid:16603128 |
Nakashima A et al. | Osteoprotegerin and bone mineral density in hemodialysis patients. | 2006 | Osteoporos Int | pmid:16604298 |
Vis M et al. | Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. | 2006 | Ann. Rheum. Dis. | pmid:16606653 |
Villa I et al. | CGRP inhibits osteoprotegerin production in human osteoblast-like cells via cAMP/PKA-dependent pathway. | 2006 | Am. J. Physiol., Cell Physiol. | pmid:16611736 |
Barreto FC et al. | Osteoporosis in hemodialysis patients revisited by bone histomorphometry: a new insight into an old problem. | 2006 | Kidney Int. | pmid:16612334 |
Swanson C et al. | Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones. | 2006 | Endocrinology | pmid:16614077 |
Demer LL and Tintut Y | Pitting phosphate transport inhibitors against vascular calcification. | 2006 | Circ. Res. | pmid:16614308 |
Vik A et al. | Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans. | 2007 | Atherosclerosis | pmid:16620835 |
Wang Q et al. | [Effect of estrogen on osteoprotegerin, osteoclast differentiation factor and macrophage colony stimulating factor mRNA expressions in ovariectomized rat bone tissue]. | 2006 | Nan Fang Yi Ke Da Xue Xue Bao | pmid:16624776 |
Dynybil C et al. | [The effect of osteoprotegerin on tendon-bone healing after reconstruction of the anterior cruciate ligament: a histomorphological and radiographical study in the rabbit]. | 2006 Mar-Apr | Z Orthop Ihre Grenzgeb | pmid:16625448 |
Yamamoto Y et al. | Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand. | 2006 | Endocrinology | pmid:16627581 |
Kanzaki H et al. | Cyclical tensile force on periodontal ligament cells inhibits osteoclastogenesis through OPG induction. | 2006 | J. Dent. Res. | pmid:16632761 |
Bersinger NA et al. | PAPP-A and osteoprotegerin, together with interleukin-8 and RANTES, are elevated in the peritoneal fluid of women with endometriosis. | 2006 | Am. J. Obstet. Gynecol. | pmid:16635455 |
Wang GF et al. | Influence of baicalin on the expression of receptor activator of nuclear factor-kappaB ligand in cultured human periodontal ligament cells. | 2006 | Pharmacology | pmid:16636611 |
Yang M et al. | The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. | 2006 | Clin. Cancer Res. | pmid:16638872 |
Hofbauer LC | Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG). | 2006 | Ann. Endocrinol. (Paris) | pmid:16639364 |
Matemba SF et al. | Regulation of osteoclastogenesis by gap junction communication. | 2006 | J. Cell. Biochem. | pmid:16639710 |
Lau YS et al. | Malignant melanoma and bone resorption. | 2006 | Br. J. Cancer | pmid:16641914 |
Makrygiannakis D et al. | Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. | 2006 | Arthritis Rheum. | pmid:16646024 |
Sylvester FA et al. | Are activated T cells regulators of bone metabolism in children with Crohn disease? | 2006 | J. Pediatr. | pmid:16647405 |
Coetzee M et al. | Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E(2) and parathyroid hormone on osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells. | 2007 | J. Nutr. Biochem. | pmid:16650751 |
Li Y et al. | Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. | 2006 | Cancer Res. | pmid:16651437 |
Takayanagi K et al. | Effects of enamel matrix derivative on bone-related mRNA expression in human periodontal ligament cells in vitro. | 2006 | J. Periodontol. | pmid:16671883 |
Vik A et al. | Serum osteoprotegerin in young survivors of myocardial infarction. | 2006 | Thromb. Haemost. | pmid:16676081 |
Zhong N et al. | [Relationship between polymorphism of parathyroid hormone and bone mineral density and relevant biochemical indicators in women]. | 2006 | Zhonghua Yi Xue Za Zhi | pmid:16677544 |
Ohmori R et al. | Association between osteoprotegerin gene polymorphism and coronary artery disease in Japanese men. | 2006 | Atherosclerosis | pmid:16678184 |
Aoki K et al. | A TNF receptor loop peptide mimic blocks RANK ligand-induced signaling, bone resorption, and bone loss. | 2006 | J. Clin. Invest. | pmid:16680194 |
Anand DV et al. | The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. | 2006 | J. Am. Coll. Cardiol. | pmid:16682312 |
Mesquita M et al. | Bone cytokines and renal osteodystrophy in peritoneal dialysis patients. | 2005 | Adv Perit Dial | pmid:16686314 |
Grzegorzewska AE and Mlot M | Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients. | 2005 | Adv Perit Dial | pmid:16686316 |
Hjelmesaeth J et al. | Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. | 2006 | J. Am. Soc. Nephrol. | pmid:16687626 |
Chaki O | [Osteoporosis]. | 2006 | Nippon Rinsho | pmid:16689336 |
Hess U | [The plasma cell myeloma--molecular pathogenesis and target therapies]. | 2006 | Ther Umsch | pmid:16689452 |
Burton A | Regulation of RANKL might reduce bone metastases . | 2006 | Lancet Oncol. | pmid:16696160 |
Wang Q et al. | [Effects of soybean isoflavones on expression levels of osteoprotegerin and osteoprotegerin ligand mRNAs in bone tissues of ovariectomized rats]. | 2006 | Zhong Xi Yi Jie He Xue Bao | pmid:16696921 |
Liu YH et al. | [Effects of kangfengshi granules on expressions of osteoprotegerin, RANKL and M-CSF in bone tissues of rats with collagen-induced arthritis]. | 2006 | Zhong Xi Yi Jie He Xue Bao | pmid:16696922 |
Gannagé-Yared MH et al. | Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. | 2006 | Clin. Endocrinol. (Oxf) | pmid:16712667 |
Rhee EJ et al. | The relationship between four single nucleotide polymorphisms in the promoter region of the osteoprotegerin gene and aortic calcification or coronary artery disease in Koreans. | 2006 | Clin. Endocrinol. (Oxf) | pmid:16712673 |
Tannehill-Gregg SH et al. | The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. | 2006 | Clin. Exp. Metastasis | pmid:16715352 |
Thommesen L et al. | Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. | 2006 | J. Cell. Biochem. | pmid:16721825 |
Liu YH et al. | [Effect of Herba Epimedii flavone on the osteoblasts metabolism in vitro]. | 2006 | Zhongguo Zhong Yao Za Zhi | pmid:16722381 |
Gori F et al. | Wdr5, a WD-40 protein, regulates osteoblast differentiation during embryonic bone development. | 2006 | Dev. Biol. | pmid:16730692 |
Geusens PP et al. | The ratio of circulating osteoprotegerin to RANKL in early rheumatoid arthritis predicts later joint destruction. | 2006 | Arthritis Rheum. | pmid:16736519 |
Shin HH et al. | Soluble glucocorticoid-induced tumor necrosis factor receptor stimulates osteoclastogenesis by down-regulation of osteoprotegerin in bone marrow stromal cells. | 2006 | Bone | pmid:16750437 |
Zauli G and Secchiero P | The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology. | 2006 | Cytokine Growth Factor Rev. | pmid:16750931 |
Tat SK et al. | OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. | 2006 | Bone | pmid:16750945 |
Sasaki N and Kusano E | [Bone and bone related biochemical examinations. Bone and collagen related metabolites. Measurement and clinical role of OPG]. | 2006 | Clin Calcium | pmid:16751691 |
Chen G et al. | Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. | 2006 | Cancer | pmid:16752412 |
Samadfam R et al. | Implication of prostaglandin receptors in the accumulation of osteoprotegerin in human osteoblast cultures. | 2006 | J. Rheumatol. | pmid:16755666 |
Nishijima Y et al. | Levels of RANKL and OPG in gingival crevicular fluid during orthodontic tooth movement and effect of compression force on releases from periodontal ligament cells in vitro. | 2006 | Orthod Craniofac Res | pmid:16764680 |
Chen WF and Wong MS | Genistein modulates the effects of parathyroid hormone in human osteoblastic SaOS-2 cells. | 2006 | Br. J. Nutr. | pmid:16768824 |
Nagae M et al. | Osteoclasts play a part in pain due to the inflammation adjacent to bone. | 2006 | Bone | pmid:16769263 |
Pérez-MartÃnez FC et al. | Immunohistochemical analysis of low-grade and high-grade prostate carcinoma: relative changes of parathyroid hormone-related protein and its parathyroid hormone 1 receptor, osteoprotegerin and receptor activator of nuclear factor-kB ligand. | 2007 | J. Clin. Pathol. | pmid:16775117 |
Kacena MA et al. | Megakaryocyte-mediated inhibition of osteoclast development. | 2006 | Bone | pmid:16782418 |
Messalli EM et al. | Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. | 2007 | Maturitas | pmid:16787719 |
Wakita T et al. | Increase in RANKL: OPG ratio in synovia of patients with temporomandibular joint disorder. | 2006 | J. Dent. Res. | pmid:16798863 |
Shin JY et al. | Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. | 2006 | Diabetes Care | pmid:16801598 |
Xiang GD et al. | The relationship between plasma osteoprotegerin and endothelium-dependent arterial dilation in type 2 diabetes. | 2006 | Diabetes | pmid:16804084 |
Galli C et al. | Osteoprotegerin and receptor activator of nuclear factor-kappa B ligand modulation by enamel matrix derivative in human alveolar osteoblasts. | 2006 | J. Periodontol. | pmid:16805686 |
Holding CA et al. | The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. | 2006 | Biomaterials | pmid:16806459 |
Kazama JJ et al. | Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism. | 2006 | Ther Apher Dial | pmid:16817791 |
Granchi D et al. | Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis. | 2006 | J Bone Joint Surg Am | pmid:16818976 |
Lee KS et al. | An antioxidant modulates expression of receptor activator of NF-kappaB in asthma. | 2006 | Exp. Mol. Med. | pmid:16819280 |
Schenk-Braat EA and Bangma CH | [The search for better markers for prostate cancer than prostate-specific antigen]. | 2006 | Ned Tijdschr Geneeskd | pmid:16821452 |
Fiore CE et al. | Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet. | 2006 | Horm. Metab. Res. | pmid:16823725 |
Fábrega E et al. | Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation. | 2006 May-Jun | Clin Transplant | pmid:16824158 |
Jeong JH et al. | Expression of RANKL and OPG in middle ear cholesteatoma tissue. | 2006 | Laryngoscope | pmid:16826057 |
Chung YH et al. | Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts. | 2006 | J. Periodont. Res. | pmid:16827722 |
Lu HK et al. | Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. | 2006 | J. Periodont. Res. | pmid:16827732 |
Théoleyre S et al. | Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. | 2006 | Biochem. Biophys. Res. Commun. | pmid:16828054 |
Valero C et al. | Osteoprotegerin and bone mass in squamous cell head and neck cancer patients. | 2006 | Calcif. Tissue Int. | pmid:16830204 |
Glass DA and Karsenty G | Canonical Wnt signaling in osteoblasts is required for osteoclast differentiation. | 2006 | Ann. N. Y. Acad. Sci. | pmid:16831912 |
Whyte MP | Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling. | 2006 | Ann. N. Y. Acad. Sci. | pmid:16831914 |
Zallone A | Direct and indirect estrogen actions on osteoblasts and osteoclasts. | 2006 | Ann. N. Y. Acad. Sci. | pmid:16831916 |
Liu XH et al. | Interactive effect of interleukin-6 and prostaglandin E2 on osteoclastogenesis via the OPG/RANKL/RANK system. | 2006 | Ann. N. Y. Acad. Sci. | pmid:16831922 |
Matsumoto T and Abe M | Bone destruction in multiple myeloma. | 2006 | Ann. N. Y. Acad. Sci. | pmid:16831932 |
Brunetti G et al. | The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease. | 2006 | Ann. N. Y. Acad. Sci. | pmid:16831934 |
Bennett BJ et al. | Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. | 2006 | Arterioscler. Thromb. Vasc. Biol. | pmid:16840715 |
Pepe J et al. | Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance. | 2006 | Br. J. Haematol. | pmid:16848794 |
Kim CH et al. | Oscillatory fluid flow-induced shear stress decreases osteoclastogenesis through RANKL and OPG signaling. | 2006 | Bone | pmid:16860618 |
Nemoto E et al. | Regulation of cementoblast function by P. gingivalis lipopolysaccharide via TLR2. | 2006 | J. Dent. Res. | pmid:16861291 |
Yamaguchi M et al. | RANKL increase in compressed periodontal ligament cells from root resorption. | 2006 | J. Dent. Res. | pmid:16861294 |
Grzegorzewska AE and MÅ‚ot M | Serum markers of bone turnover in dialyzed patients separated according to age. | 2006 | Int Urol Nephrol | pmid:16868703 |
Robertson KM et al. | Cholesterol-sensing receptors, liver X receptor alpha and beta, have novel and distinct roles in osteoclast differentiation and activation. | 2006 | J. Bone Miner. Res. | pmid:16869726 |
Kastritis E et al. | Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support. | 2006 | Clin Lymphoma Myeloma | pmid:16879774 |
Schwarz C et al. | Diagnosis of renal osteodystrophy. | 2006 | Eur. J. Clin. Invest. | pmid:16884394 |
Michou L et al. | [Molecular analysis of Paget's disease of bone]. | 2007 Apr-May | Pathol. Biol. | pmid:16884862 |
Karosi T et al. | Detection of osteoprotegerin and TNF-alpha mRNA in ankylotic Stapes footplates in connection with measles virus positivity. | 2006 | Laryngoscope | pmid:16885748 |
Franklin M et al. | Dried plum prevents bone loss in a male osteoporosis model via IGF-I and the RANK pathway. | 2006 | Bone | pmid:16890505 |
Mikosch P et al. | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer. | 2006 | Eur. J. Clin. Invest. | pmid:16893379 |
Ziółkowska H and Roszkowska-Blaim M | [Osteoprotegerin and calcium-phosphorus metabolism parameters in children with chronic renal failure]. | 2006 | Prz. Lek. | pmid:16898492 |
Baek KH et al. | Changes in the serum sex steroids, IL-7 and RANKL-OPG system after bone marrow transplantation: influences on bone and mineral metabolism. | 2006 | Bone | pmid:16905375 |
Bernstein CN | Inflammatory bowel diseases as secondary causes of osteoporosis. | 2006 | Curr Osteoporos Rep | pmid:16908001 |
Mochizuki Y et al. | Correlation between serum osteoprotegerin and biomarkers of bone metabolism during anti-thyroid treatment in patients with Graves' disease. | 2006 | Horm. Res. | pmid:16912510 |
Roudier MP et al. | Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats. | 2006 | Clin. Exp. Metastasis | pmid:16912914 |
Kawasaki K et al. | Effects of aging on RANKL and OPG levels in gingival crevicular fluid during orthodontic tooth movement. | 2006 | Orthod Craniofac Res | pmid:16918678 |
Menezes R et al. | Receptor activator NFkappaB-ligand and osteoprotegerin protein expression in human periapical cysts and granulomas. | 2006 | Oral Surg Oral Med Oral Pathol Oral Radiol Endod | pmid:16920551 |
Neumann E | [New pathophysological relevant metabolic pathways in osteoporosis. Future innovative therapies?]. | 2006 | Z Rheumatol | pmid:16924451 |
Rucci N et al. | Modeled microgravity stimulates osteoclastogenesis and bone resorption by increasing osteoblast RANKL/OPG ratio. | 2007 | J. Cell. Biochem. | pmid:16927271 |
Wang L et al. | [Inhibitory effect of diacerein on osteoclastic bone destruction and its possible mechanism of action]. | 2006 | Yao Xue Xue Bao | pmid:16927832 |